Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationActa Ophthalmol 2012, 90(7):603-8
AbstractTopically applied carbonic anhydrase inhibitors (CAIs) in eye drop solutions are commonly used to treat glaucoma. However, local eye irritation and multiple daily administrations may hamper their clinical usefulness. Aqueous eye drop formulations that improve their topical bioavailability and reduce their eye irritation can improve their clinical efficacy. Earlier studies showed that dorzolamide and closely related CAIs are more effectively delivered into the eye from acidic eye drop solutions than from comparable neutral solutions. Consequently, dorzolamide was marketed as an aqueous pH 5.6 eye drop solution (Trusopt(®) , Merck). Later, it was shown that increasing the pH of the eye drops from pH 5.6 to physiologic pH significantly reduced their local irritation. Earlier attempts to use cyclodextrins (CDs) as ocular penetration enhancers in dorzolamide eye drop solutions failed since; although the CDs were able to enhance the aqueous solubility of dorzolamide, increasing the pH from 5.6 to physiologic pH reduced the ability of the drug to permeate into the eye. Later, it was discovered that formulating the drug as aqueous dorzolamide/γCD eye drop microparticle suspension resulted in significant bioavailability enhancement. The solid dorzolamide/γCD microparticles are mucoadhesive and release dorzolamide into the aqueous tear fluid for extended time period. Consequently, sustained high dorzolamide concentrations in aqueous humour and various eye tissues were observed after single administration of the aqueous dorzolamide/γCD eye drop microsuspension. The microsuspension has a potential of being developed into a once-a-day eye drop product. This article reviews the physicochemical properties of dorzolamide, its permeation characteristics and topical bioavailability.
DescriptionTo access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.
RightsArchived with thanks to Acta ophthalmologica
- Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension.
- Authors: Jansook P, Stefánsson E, Thorsteinsdóttir M, Sigurdsson BB, Kristjánsdóttir SS, Bas JF, Sigurdsson HH, Loftsson T
- Issue date: 2010 Oct
- Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration.
- Authors: Sigurdsson HH, Stefánsson E, Gudmundsdóttir E, Eysteinsson T, Thorsteinsdóttir M, Loftsson T
- Issue date: 2005 Jan 20
- Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles.
- Authors: Park CG, Kim YK, Kim SN, Lee SH, Huh BK, Park MA, Won H, Park KH, Choy YB
- Issue date: 2017 Apr 30
- Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid.
- Authors: Jóhannesson G, Moya-Ortega MD, Ásgrímsdóttir GM, Lund SH, Thorsteinsdóttir M, Loftsson T, Stefánsson E
- Issue date: 2014 Sep
- Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.
- Authors: Kadam RS, Jadhav G, Ogidigben M, Kompella UB
- Issue date: 2011 Sep